
usd may pm et
summari provid advanc scientif instrument relat product servic
world-wide pharmaceut industri govern academ custom
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
adjust revenu fell short
revenu guidanc mere
yoy sharp slowdown compar
yoy growth result
doubl digit declin sale apac region
mainli trigger declin sale
china total net revenu
segment basi sale declin yoy
diagnost segment total due
soft apac region particularli
immunodiagnost reproduct health
franchis result outbreak
segment total also wit
slowdown growth compar previou
quarter yoy due soft food
appli market
estim revenu around
midpoint
european sale continu grow doubl
digit sale remain resili
mid-singl digit neg impact
felt end quarter
view howev expect sale
declin market around total
result loss demand caus
see mix posit neg trend
unfold next year think
challeng year
compani expect sale declin
throughout year across differ region
due loss demand caus
continu see solid long-term outlook
diagnost segment sale
due lead posit reproduct
screen pregnanc diagnost like
key growth driver futur
estim less third global
pregnanc receiv health screen yet
see new risk emerg patient avoid
go hospit test due
may post earn releas lower
target price ep
estim histor forward
price-to-earnings averag expect sale declin
due disrupt caus
due uncertainti relat length
depth crisi prolong
neg impact anticip
import risk view risk see
includ slowdown emerg market birth
rate re-escal intern trade
risk assess reflect strong track record
technolog innov divers global client
base firm strong posit rapidli
grow reproduct diagnost field provid
long-term demand tailwind see benefit
partial off-set somewhat volatil sale pattern
note sale growth neg sever quarter
also see risk associ
strength sever much larger diversifi
competitor particularli seek market share gain
area competitor may alreadi firmli
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice-president
corpor overview inc provid technolog product servic
diagnost research environment industri laboratori servic market compani oper
two segment discoveri analyt solut revenu oper profit
diagnost revenu oper profit
discoveri analyt solut da technolog product segment help life
scienc research better understand diseas develop treatment addit allow
monitor manag contamin toxic chemic impact environ food
suppli da serv life scienc appli market describ
life scienc market serv da consist research market laboratori servic market
life scienc product sold da support pharmaceut biotech compani academ
institut discov develop better treatment therapeut fight diseas da
onesourc laboratori servic busi also provid life scienc custom servic design improv
laboratori product time reduc mainten cost
appli market serv da consist environment food industri market environment
custom use da analyt technolog servic understand character
environ like air water soil qualiti exampl da solut help ensur complianc
regulatori standard protect puriti world water suppli detect harm substanc
includ trace metal lead organ pollut pesticid food produc use da
instrument confirm food qualiti includ level moistur grain level fat butter
well detect presenc potenti danger contamin lead mercuri milk
industri custom chemic semiconductor electron energi lubric petrochem
produc use da technolog primarili qualiti assur capac
diagnost segment sell product servic hospit medic lab clinician medic
research profession focu reproduct health autoimmun diseas screen appli
genom diagnost product use clinic set provid earli detect genet
disord pregnanc earli childhood also use infecti diseas test
segment also serv laboratori custom util instrument reagent softwar
test screen genet abnorm certain disord diseas includ syndrom
hypothyroid infertil variou metabol condit diagnost product also support
genom research analysi lab workflow use next-gener dna sequenc applic
oncolog drug discoveri
employ approxim sale servic repres countri directli market
servic product across globe market lack sale servic forc util
third-parti distributor get product custom
product sold often serv custom conduct cutting-edg research develop
 biopharmaceut medic industri applic accordingli must consist invest
 provid product anticip continu evolv need technolog
advanc custom base spent revenu program
corpor strategi histor pursu capit alloc strategi balanc small
bolt-on acquisit share repurchas dividend debt reduct howev start
deviat strategi make acquisit prioriti futur growth made major acquisit
decemb expand diagnost busi acquir immun lead
diagnost compani focus autoimmun infecti diseas allergi test subsequ
made four acquisit four aim portfolio transform provid
end-to-end solut custom strengthen da segment
manag decemb prahlad singh appoint ceo replac robert franci
friel step end chairman ceo consid singh focu next
phase growth evolut believ could right path forward compani
financi trend sale grown repres three-year
compound annual growth rate compound-annual-growth-rate sale growth materi impact immun
acquisit drove sale increas newli acquir compani
year particularli meizheng food safeti test cisbo kit reagent contribut
increas top-lin revenu target organ growth top-lin revenu
rang contribut acquisit roughli total revenu
view achiev start see full-year contribut cisbo meizheng
sustain dividend polici view histor compani balanc sheet
low moder debt level net debt/ebitda rang rang last ten year net
debt/ebitda stood decemb view allow distribut cash
dividend everi quarter amount per share period decemb
offer dividend yield dividend pay-out ratio stood
expect continu pay dividend maintain similar low dividend yield
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
life scienc tool servic sub-industri
expect earn growth remain
posit slow sharpli rate achiev
risk factor see slower
biopharmaceut spend growth
prolong uncertainti due
nation institut nih budget
grow rapidli last three
year materi increas fund
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih fy
sep budget grew vs prior year
follow growth fy
mark major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
prolifer advanc health care around
world continu drive demand growth
lst firm long-term emerg
market particularli china india
rapidli grow middl class gain
access advanc health care
drive suppli need new expand
medic research lab facil howev
due rapidli spread coronaviru
result suppli chain travel disrupt
expect slowdown demand next
think biopharmaceut firm moder
 spend growth due
outbreak
estim total spend
global biopharmaceut compani grew
annual averag expect slow
see
delay new clinic trial halt
on-go studi major pharmaceut
compani larg swath biopharma
typic flow lst firm suppli
depart research tool softwar
contract servic accordingli think
slowdown biopharma growth
reduc tailwind mani lst firm
receiv client group recent
expect recent coronaviru outbreak
oper result first half
china small promis market
lst compani around total
sector revenu seen number
disrupt due travel restrict
temporari closur site china
expect loss stem chines
oper limit expect
loss increas
time certain lst compani
well-posit benefit outbreak
close work
govern hospit develop test
kit sequenc genom viru
fda issu emerg author
number lst firm diagnost
serolog test use
laboratori detect
consider need respond grow
daili diagnost demand point
 lst compani quickli
absorb demand
year date april
servic declin compar
decreas experienc
broader healthcar sector
decreas overal
index life scienc tool
much faster rise
healthcar sector rise
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold opinion share inc
cut target ep estim line
pki histor forward price-to-earnings averag trim ep
estim expect sale declin europ
due cut ep estim
ep vs estim
consensu adjust revenu yoy sharp slowdown compar
yoy growth result double-digit declin sale
apac region mainli trigger declin sale china
total net revenu headwind segment basi sale declin
yoy diagnost segment total due soft
immunodiagnost reproduct health franchis result
total also wit slowdown growth compar previou quarter
yoy due soft food appli market /sel hardi
et cfra lift opinion share inc hold sell
drop target price ep estim
maintain ep estim sell recommend
share sinc april concern forward price-to-earnings valuat
roughli becom rich compar averag
respect neg impact analyt instrument margin
escal border tariff fulli appreci view share
declin sinc sell recommend compar flat perform
 forward price-to-earnings multipl compress bring share
much closer fair valu estim accordingli move share hold
still expect tariff drive market share loss discoveri analyt
segment think strong posit rapidli grow reproduct
diagnost market warrant slight valuat premium
pm et cfra maintain buy opinion share thermo fisher
scientif inc maintain price target
ep estim share major analyt instrument maker
sharpli today includ
around midday believ sell-off
partial relat ad chines firm export blacklist
monday increas tension trade war view
hurt global suppli chain instrument maker disagre
reaction share howev think compani global divers
product facil uniqu lack single-sourc suppli relationship
give much greater flexibl peer avoid tariff-driven cost
increas view advantag actual allow take signific
instrument market share smaller firm like etc
reli china revenu wherea gener
roughli sale /colin scarola
et cfra maintain hold opinion share inc
lift target higher forward price-to-earnings
unchang ep estim line
histor forward price-to-earnings averag reflect improv view follow
better-than-expect adj ep revenu despit on-going concern
qualiti earn growth keep ep estim
stand mid-point pki ep guidanc rang
post ep vs consensu beat
pki adjust revenu grew yoy adjust ep continu
grow even faster yoy top-lin revenu growth driven yoy
growth main discoveri analyt solut divis sale
led better-than-anticip growth life scienc food franchis
diagnost segment sale grew yoy led mid-teen growth
immun produc wide rang reagent medic laboratori
pm et cfra maintain hold opinion share inc
lift target higher revis price-to-earnings
ep estim slightli pki histor forward price-to-earnings
averag maintain ep estim rais
rais reflect improv
outlook follow resolut phase one deal
china chines sale make roughli pki total revenu
tariff-driven cost increas pose signific econom risk compani
view moreov believ appoint prahlad singh ceo
could right path forward compani consid
singh focu next phase growth evolut yet
remain cautiou qualiti earn growth prefer remain neutral
spike receiv inventori day could indic
may extend custom payment term combat weaken demand
age inventori view sel hardi
et cfra maintain hold opinion share inc
keep target price ep estim --
histor forward price-to-earnings averag lift ep estim
lower start adjust ep
vs beat consensu grew revenu yoy
adjust ep even faster yoy howev see sever reason
question qualiti earn growth one doubl
non-gaap adjust purchas account restructur despit
signific recur expens busi strategi
without larg yoy increas adjust ep growth closer
yoy well consensu addit concern respect day
yoy increas receiv day inventori day indic us
may extend custom payment term combat weaken demand
inventori concern inform hold opinion despit peer
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
